CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Wave Life Sciences, Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Wave Life Sciences, Inc
733 Concord Avenue
Phone: (617) 949-2900p:617 949-2900 CAMBRIDGE, MA  02138  United States Ticker: WVEWVE
This company ceased filing statements with the SEC on 8/10/2026.
Business Summary
Wave Life Sciences, Inc. is a clinical-stage biotechnology company focused on ribonucleic acid (RNA) medicines (also known as oligonucleotides), or those targeting RNA, to transform human health. The Company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNA interference (RNAi) (SpiNA) and RNA editing (AIMers), provides unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company's pipeline is focused on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs and also includes clinical programs for Duchenne muscular dystrophy (DMD) and Huntington's disease, as well as several preclinical programs utilizing its versatile RNA medicines platform.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202612/31/2025YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Christian O.Henry 58 10/1/2017 11/10/2016
President, Chief Executive Officer, Director Paul B.Bolno 52 4/1/2014 12/1/2013
Chief Financial Officer KyleMoran 55 12/5/2020 7/1/2014
8 additional Officers and Directors records available in full report.

Business Names
Business Name
WAVE Life Sciences Ireland Limited
Wave Life Sciences Japan
WAVE Life Sciences Japan, Inc.
4 additional Business Names available in full report.

General Information
Number of Employees: 317 (As of 12/31/2025)
Outstanding Shares: 197,228,058 (As of 10/8/2026)
Shareholders: 7
Stock Exchange: NASD
Email Address: info@wavelifesci.com


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, October 27, 2026